Overcoming insulin resistance with ciliary neurotrophic factor

Handb Exp Pharmacol. 2011:(203):179-99. doi: 10.1007/978-3-642-17214-4_9.

Abstract

The incidence of obesity and related co-morbidities such as insulin resistance, dyslipidemia and hypertension are increasing at an alarming rate worldwide. Current interventions seem ineffective to halt this progression. With the failure of leptin as an anti-obesity therapeutic, ciliary neurotrophic factor (CNTF) has proven efficacious in models of obesity and leptin resistance, where leptin proved ineffective. CNTF is a gp130 ligand that has been found to act centrally and peripherally to promote weight loss and insulin sensitivity in both human and rodent models. Future research into novel gp130 ligands may offer new candidates for obesity-related drug therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Obesity Agents*
  • Ciliary Neurotrophic Factor / pharmacology*
  • Ciliary Neurotrophic Factor / therapeutic use*
  • Cytokine Receptor gp130 / physiology
  • Diabetes Mellitus, Type 2 / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin Resistance / physiology*
  • Ligands
  • Obesity / drug therapy
  • Receptors, Leptin / antagonists & inhibitors
  • Receptors, Leptin / physiology
  • Signal Transduction / physiology

Substances

  • Anti-Obesity Agents
  • Ciliary Neurotrophic Factor
  • Hypoglycemic Agents
  • Ligands
  • Receptors, Leptin
  • Cytokine Receptor gp130